Malaria in children is often treated by administration of Artemisinin, as they have a broad efficiency for multiple Plasmodium species. In Papua New Guinea, artemether-lumefantrine is the first-line of treatment for uncomplicated malaria, but its efficiency is limited against P. vivax.
The study reveals that artemisinin-naphthoquine combination therapy should have greater activity in vivax malaria. The reason for this is that naphthoquine is slower than lumefantrine to be eliminated. The authors compared artemether-lumefantrine treatment with artemisinin-naphthoquine treatment.
Using a randomized, controlled trial study design including 186 children with P. falciparum infections and 47 children with P. vivax infections, the researchers found that artemisinin-naphthoquine was non-inferior to artemether-lumefantrine for treating P. falciparum but was more effective for treating P. vivax.
The original publication can be accessed at: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001773
Disclaimer: This article does not reflect any personal views of the authors/editors